Non-animal source cell blood serum substitute and use thereof

Abstract

The invention provides a non-animal origin cell cultivating serum substitute (PLT) and applications thereof. The PLT is prepared by the following method: 3 to 5 volume units of O-typed buffy coats and 1 volume unit of AB-typed plasma are mixed; 300 to 400 grams of the mixture is centrifuged; a supernatant is extracted as 1 volume unit of platelet-rich plasma; the platelet-rich plasma is filtered so as to remove leucocyte, stored under cryopreservation at the temperature below minus 10 DEG C for standby, and unfrozen at the temperature of 30 to 37 DEG C before use, and 3000 to 5000 grams of the platelet-rich plasma is centrifuged so as to remove platelet membrane fragments, thus obtaining the non-animal origin cell cultivating serum substitute. The non-animal origin cell cultivating serum substitute has following essential advantages: the PLT can be used as fetal bovine serum substitute in cell cultivation, thus avoiding animal-origin ingredients in cell cultivation, quickening cell multiplication and consequently satisfying the requirements of clinical security and operation period shortening, and the non-animal origin cell cultivating serum substitute is applicable not only to mesenchymal stem cells, but also to the multiplication cultivation of other human origin cells.

Description

(1) Technical field

[0001] The invention relates to a non-animal source cell culture serum substitute and its application in cell culture as a substitute for fetal bovine serum and the like. (2) Background technology

[0002] In conventional cell culture and expansion processes, animal-derived serum such as fetal bovine serum (FBS) is an essential additive for cell expansion.

[0003] In the cell therapy of regenerative medicine, there are not only quantitative requirements for the seed cells used in clinical practice, but also the need to ensure their safety and effectiveness. Although the participation of animal-derived serum in cell culture can meet the quantitative requirements, it brings unsafe hidden dangers to clinical treatment. However, autologous serum is inconvenient to obtain and use, and cannot achieve the effect of rapid cell expansion, nor can it meet the needs of clinical cell therapy for the number of cells. (3) Contents of the invention

[0004] The obje...